Oticon Intent vs Otofonix Groove

The Oticon Intent is a premium behind-the-ear prescription hearing aid released in 2024, priced at $4,898 and earning an A grade with a SoundScore of 4.8/5 in our lab testing. This places it at #4 among 39 prescription hearing aids tested, within the top 8% of its category. In our testing, the Intent demonstrates notable strengths in speech performance, scoring 0.54 points above the category average for speech in quiet and a substantial 0.95 points above average for speech in noise. Music streaming is a particular highlight, measuring 1.24 points above the category average with a strong 4.0/5 score. Feedback handling is excellent at 5.0/5, slightly exceeding the already-high category average. The primary limitation revealed in our testing is own-voice comfort, which scores 1.3/5—a low absolute score that falls 1.40 points below the category average. Users sensitive to the sound of their own voice may find this characteristic noticeable. This is a common trade-off in devices optimized for speech audibility. The Oticon Intent is well-suited for users prioritizing speech understanding across varied listening environments and high-quality audio streaming. It has earned HearAdvisor's Expert's Choice Award in both 2023 and 2024. Shoppers in this premium price tier may also consider the Phonak Sphere Infinio (#2) or the lower-priced Oticon Zeal, which offers strong performance at a reduced cost.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE ranks #38 of 39 devices in the prescription hearing aid category, placing it in the bottom 5% of its class. In our testing, the Groove demonstrated excellent feedback handling at 5.0/5, scoring 0.28 points above the category average. This represents a genuine strength, with the device maintaining stability during our standardized challenge motions. However, speech performance was significantly limited, with speech in quiet scoring 1.0/5 (2.40 points below the category average of 3.40) and speech in noise also at 1.0/5 (1.11 points below average). Music streaming was not functional in our tests, scoring 0.0/5 against a category average of 2.76. Own-voice comfort also fell well below typical prescription hearing aid performance at 0.4/5, which is 2.30 points below the category average. At this price point, several lower-cost alternatives delivered stronger overall performance in our testing. Consumers seeking value in the prescription category may want to explore other options, though those requiring robust feedback control in a rechargeable BTE format may find the Groove's stability noteworthy despite its other limitations.